1
`
`Grun. Exh. 1052
`PGR for U.S. Patent No. 9,867,839
`
`Grün. Exh. 1014
`PGR for U.S. Patent No. 10,052,338
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your
`submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of
`the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2)
`furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the
`US. Patent and Trademark Office is to process and/or examine your submission related to a patent application or
`patent.
`If you do not furnish the requested information, the US. Patent and Trademark Office may not be able to
`process and/or examine your submission, which may result in termination of proceedings or abandonment of the
`application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1. The information on this form will be treated confidentially to the extent allowed under the Freedom of
`Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may
`be disclosed to the Department of Justice to determine whether disclosure of these records is required by the
`Freedom of Information Act.
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence
`to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of
`settlement negotiations.
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request involving an individual, to whom the record pertains, when the individual has requested assistance from
`the Member with respect to the subject matter of the record.
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having
`need for the information in order to perform a contract. Recipients of information shall be required to comply
`with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of
`records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property
`Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes
`of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C.
`218(0)).
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General
`Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency’s
`responsibility to recommend improvements in records management practices and programs, under authority of
`44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing
`inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such
`disclosure shall not be used to make determinations about individuals.
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of
`the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a
`record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record
`was filed in an application which became abandoned or in which the proceedings were terminated and which
`application is referenced by either a published application, an application open to public inspection or an issued
`patent.
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.
`
`2
`
`

`

`PTO/AINM (12-13)
`Approved for use through 01131/2014. OMB 0651-0032
`US Patent and Trademark Office; US DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`-
`
`-
`
`
`
`INHIBITORS OF OSTEOCLAST ACTIVITY FOR TREATING ARTHRITIS
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`Title of Invention
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`
`document may be printed and included in a paper filed application.
`
`Secrecy Order 37 CFR 5.2
`I:I Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`Inventor Information:
`
`
`
`Inventor 1
`Legal Name
`
`Prefix Given Name
`Middle Name
`Family Name
`Suffix
`-———-
`Residence Information (Select One) 6) US Residency 0 Non US Residency 0 Active US Military Service
`
`
` StatelProvince Country of Residence I I US
`
`Mailing Address of Inventor:
`Address 1
`630 Fifth Avenue, Suite 2000
`
`generated within this form by selecting the Add button.
`
`Address 2
`
`City
`Postal Code
`
`New York
`
`StateIProvince
`
`NY
`
`All
`
`Inventors Must Be Listed - Additional
`
`Inventor Information blocks may be
`
`Correspondence Information:
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`
`D An Address is being provided for the correspondence Information of this application.
`Customer Number
`
`45200 Email Address
`
`OCpatents@klgates.com
`
`Application Information:
`
`
`
`Title of the Invention INHIBITORS OF OSTEOCLAST ACTIVITY FOR TREATING ARTHRITIS
`
`Small Entity Status Claimed
`Attorney Docket Number 195860300073
`Nonprovisional
`Application Type
`
`Subject Matter
`
`Total Number of Drawing Sheets (if any)
`
`Suggested Figure for Publication (if any)
`
` Utility
`
`
`Filing By Reference:
`
`EFS Web 2.2.11
`
`3
`
`

`

`PTO/AIN‘M (12—13)
`Approved for use through 01131/2014. OMB 0651-0032
`US Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995. no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`Attorney Docket Number
`195860300073
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Title Of Invention
`
`INHIBITORS OF OSTEOCLAST ACTIVITY FOR TREATING ARTHRITIS
`
`filed application
`
`Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate secti0n(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").
`
`For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR 157(3).
`
`Application number of the previously
`
`Filing date (YYYY-MM-DD)
`
`Intellectual Property Authority or Country i
`
`Publication Information:
`
`
`D Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`Request Not to Publish. I hereby request that the attached application not be published under
`35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`
`publication at eighteen months after filing.
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below.
`If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`
` Please Select One:
`(9 Customer Number
`0 us Patent Practitioner 0 Limited Recognition (37 CFR 11.9)
`
`Customer Number 45200
`
`
`Domestic Benefithational Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C.119(e),120,121, or 365(c) or indicate National Stage
`entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required
`by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the application number blank.
`
`
`Prior Application Status
`Pending
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`Continuation in part of
`
`14/446184
`
`2014—07—29
`
`
`
`
`Prior Application Status
`
`Application
`
`Patented
`
`PriorApplication
`
`Filing Date
`
`_emove
`
`-lssue Date
`
`14/446184
`
`14/288716
`
`2014-05-28
`
`8835650
`
`2014-09-16
`
`
`Prior Application Status
`Pending
`EFS Web 2.2.11
`
`4
`
`

`

`PTO/AlA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`Attorney Docket Number 195860300073
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`INHIBITORS OF OSTEOCLAST ACTIVITY FOR TREATING ARTHRITIS
`
`Title of Invention
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`14/288716
`
`Claims benefit of provisional
`
`61/933608
`
`Filing Date (YYYY-MM-DD)
`2014—01 —30
`
`Prior Application Status
`Pending
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`— Continuation in part of
`
`14/279229
`
`2014—05—15
`
`Application
`
`.
`
`.
`
`PriorApplication
`
`Filing Date
`
`Issue Date
`
`2014—08—12
`8802658
`2013—10-25
`14/063979
`Continuation of
`14/279229
`
`
`
`Prior Application Status
`Pending
`
`Application Number
`Continuity Type
`Prior Application Number
`Filing Date (YYYY-MM-DD)
`
`14/063979
`
`Continuation in part of
`
`13/894274
`
`2013-05-14
`
`
`
`
`Application Number
`Continuity Type
`Prior Application Number
`Filing Date (YYYY-MM-DD)
`
`13/894274
`Claims benefit of provisional
`61/646538
`2012—05—14
`
`Prior Application Status
`
`Expired
`
`Filing Date (YYYY-MM-DD)
`Prior Application Number
`Continuity Type
`Application Number
`
`13/894274
`Claims benefit of provisional
`61/647478
`2012—05—1 5
`
`
`Prior Application Status
`Expired
`
`Application Number
`Continuity Type
`Prior Application Number
`Filing Date (YYYY-MM-DD)
`
`13/894274
`
`Claims benefit of provisional
`
`61/654292
`
`2012-06-01
`
`
`Application Number
`Continuity Type
`Prior Application Number
`Filing Date (YYYY-MM-DD)
`
`13/894274
`Claims benefit of provisional
`61/654383
`2012—06—01
`
`Prior Application Status
`
`Expired
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`13/894274
`
`Claims benefit of provisional
`
`61/655527
`
`2012—06—05
`
`
`Prior Application Status
`Expired
`
`Filing Date (YYYY-MM-DD)
`Prior Application Number
`Continuity Type
`Application Number
`
`13/894274
`Claims benefit of provisional
`61/655541
`2012-06-05
`
`Expired
`Prior Application Status
`
`Application Number
`Continuity Type
`Prior Application Number
`Filing Date (YYYY-MM-DD)
`
`13/894274
`Claims benefit of provisional
`61/764563
`2013—02—14
`
`Prior Application Status
`
`Expired
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`13/894274
`
`EFS Web 2.2.11
`
`Claims benefit of provisional
`
`61/762225
`
`2013-02-07
`
`5
`
`

`

`PTO/AlA/‘M (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`Attorney Docket Number 195860300073
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`INHIBITORS OF OSTEOCLAST ACTIVITY FOR TREATING ARTHRITIS
`
`Title Of Invention
`
`
`Prior Application Status
`Expired
`
`
`Application Number
`Continuity Type
`Prior Application Number
`Filing Date (YYYY-MM-DD)
`
`
`13/894274
`Claims benefit of provisional
`61/767647
`2013—02—21
`
`Prior Application Status
`
`Expired
`
`
`by selecting the Add button.
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`13/894274
`
`Claims benefit of provisional
`
`61/767676
`
`2013—02—21
`
`
`Prior Application Status
`Expired
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`13/894274
`
`Claims benefit of provisional
`
`61/803721
`
`2013-03-20
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55_(d). When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (PDX) lthe information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(h)(1) and (2). Under the PDX program, applicant bears the ultimate
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).
`
`
`
`
`
`Application Number
`
`Country I
`
`Filing Date (YYYY—MM-DD)
`
`Access Codei (if applicable)
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`
`Add button. Add
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`
`Applications
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`D 16, 2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`
`16, 2013, will be examined under the first inventor to file provisions of the AIA.
`
`EFS Web 2.2.11
`
`6
`
`

`

`PTO/AIN‘M (12-13)
`Approved for use through 01131/2014. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`Attorney Docket Number
`195860300073
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`INHIBITORS OF OSTEOCLAST ACTIVITY FOR TREATING ARTHRITIS
`
`Title Of Invention
`
`Authorization to Permit Access:
`
`D Authorization to Permit Access to the Instant Application by the Participating Offices
`
`If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO),
`the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO),
`and any other intellectual property offices in which a foreign application claiming priority to the instant patent application
`is filed access to the instant patent application. See 37 CFR 114(0) and (h). This box should not be checked ifthe applicant
`does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority
`to the instant patent application is filed to have access to the instant patent application.
`
`In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy ofthe instant patent application with respect
`to: 1) the instant patent application—as—filed; 2) any foreign application to which the instant patent application
`claims priority under 35 U.S.C. 119(a)—(d) if a copy of the foreign application that satisfies the certified copy requirement of
`37 CFR 1.55 has been filed in the instant patent application; and 3) any US application—as—filed from which benefit is
`sought in the instant patent application.
`
`Applicant Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing this Authorization.
`
`
`1
`Applicant
`lfthe applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`
`@ Assignee
`
`0 Legal Representative under 35 U.S.C. 117
`
`0 Joint Inventor
`
`
`
`0 Person to whom the inventor is obligated to assign. 0 Person who shows sufficient proprietary interest
`
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`Name of the Deceased or Legally lncapacitated Inventor::|
`If the Applicant is an Organization check here.
`
`organization Name
`
`Antecip Bioventures ll LLP
`
`EFS Web 2.2.11
`
`7
`
`

`

`PTO/AIN‘M (12-13)
`Approved for use through 01131/2014. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995. no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`195860300073
`Attorney Docket Number
`
`
`Title Of Invention
`
`INHIBITORS OF OSTEOCLAST ACTIVITY FOR TREATING ARTHRITIS
`
`Mailing Address Information:
`
`Address 1
`
`630 Fifth Avenue, Suite 2000
`
`Address 2
`
`City
`StatelProvince
`
`
`
`
`Country I
`Phone Number
`
`Email Address
`
`Postal Code
`Fax Number
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`Add
`
`Assignee Information including Non-Applicant Assignee Information:
`
`
`Providing assignment information in this section does not subsitute for compliance with any requirement of part 3 of Title 37 of CFR to
`have an assignment recorded by the Office.
`
`
`Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent
`application publication . An assignee—applicant identified in the "Applicant Information" section will appear on the patent application
`publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`
`Remove
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`|:|
`
`
`
`Middle Name
`
`Family Name
`
`
`
`Email Address
`
`Given Name
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`Address 1
`
`Address 2
`
`
`
`Phone Number
`
`Fax Number
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`.
`selecting the Add button.
`
`
`Add
`
`EFS Web 2.2.11
`
`8
`
`

`

`PTO/AIN‘M (12—13)
`Approved for use through 01131/2014. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`Attorney Docket Number
`195860300073
`
`INHIBITORS OF OSTEOCLAST ACTIVITY FOR TREATING ARTHRITIS
`
`Title Of Invention
`
`
`Signature:
`
`NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and
`certifications
`
`
`
`
`
`Registration Number
`
`Date (YYYY-MM-DD)lBrentA.JohnsonlSignature 2014—11—07
`
`
`
`First Name
`
`Brent A.
`
`Last Name
`
`Add
`Additional Signature may be generated within this form by selecting the Add button.
`
`
`This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount oftime you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, US. Patent and
`Trademark Office, US. Department of Commerce, PO. Box 1450, Alexandria, VA 22313—1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`EFS Web 2.2.11
`
`9
`
`

`

`Privacy Act Statement
`
`
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to
`a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that:
`(1) the general authority for the collection
`of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is
`used by the U.S. Patent and Trademark Office is to process andlor examine your submission related to a patent application or patent.
`If you do not
`furnish the requested information, the US Patent and Trademark Office may not be able to process and/or examine your submission, which may
`result in termination of proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552)
`and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine
`whether the Freedom of Information Act requires disclosure of these records.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or
`administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
`
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an
`individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of
`the record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in
`order to perform a contract. Recipients of information shall be required to comply with the requirements ofthe Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed,
`as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security
`review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hislher designee,
`during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records
`management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the
`GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such
`disclosure shall not be used to make determinations about individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuan
`to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37
`CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were
`terminated and which application is referenced by either a published application, an application open to public inspections or an issued
`patent.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the
`USPTO becomes aware of a violation or potential violation of law or regulation.
`
`
`EFS Web 2.2.11
`
`10
`
`10
`
`

`

`PTO/AlA/01 (06-12)
`Approved for use through 01/31/2014. OMB 0651-0032
`US Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`
`DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
`APPLICATION DATA SHEET (37 CFR 1.76)
`
`Title of
`Invention
`
`ENHIBETORS OF OSTEOCLAST ACTIVITY FOR TREATING ARTE-tRETES
`
`As the below named inventor, I hereby declare that:
`
`This declaration
`is directed to:
`
`IE The attached application, or
`
`D United States application or PCT international application number
`filed on
`
`The above-identified application was made or authorized to be made by me.
`
`I believe that I am the original inventor or an original joint inventor ofa claimed invention in the application.
`
`I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001
`by fine or imprisonment of not more than five (5) years, or both.
`
`
`
`WARNING:
`
`Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may
`contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers
`(other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO
`to support a petition or an application.
`lfthis type of personal information is included in documents submitted to the USPTO,
`petitioners/applicants should consider redacting such personal information from the documents before submitting them to the
`USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the
`application (unless a non—publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance ofa
`patent. Furthermore, the record from an abandoned application may also be available to the public if the application is
`referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms
`PTO—2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.
`
`LEGAL NAME OF INVENTOR
`
` f
`
`Inventor: Harriet Tabuteau
`Date (optional) ;
`.
`i
`Signature:.Herriot Taouteau/
`
`Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have
`been previously filed. Use an additional PTO/AIAI01 form for each additional inventor.
`
`This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and
`by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to
`complete, including gathering, preparing. and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any
`comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.
`Patent and Trademark Office, US. Department of Commerce, PO. Box 1450, Alexandria, VA 22313—1450. DO NOT SEND FEES OR COMPLETED FORMS TO
`THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.
`
`11
`
`11
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection
`with your submission of the attached form related to a patent application or patent. Accordingly,
`pursuant to the requirements of the Act, please be advised that: (1) the general authority for the
`collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary;
`and (3) the principal purpose for which the information is used by the US. Patent and Trademark
`Office is to process and/or examine your submission related to a patent application or patent. If you do
`not furnish the requested information, the US. Patent and Trademark Office may not be able to
`process and/or examine your submission, which may result in termination of proceedings or
`abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1 . The information on this form will be treated confidentially to the extent allowed under the
`Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from
`this system of records may be disclosed to the Department of Justice to determine whether
`disclosure of these records is required by the Freedom of Information Act.
`A record from this system of records may be disclosed, as a routine use, in the course of
`presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to
`opposing counsel in the course of settlement negotiations.
`A record in this system of records may be disclosed, as a routine use, to a Member of
`Congress submitting a request involving an individual, to whom the record pertains, when the
`individual has requested assistance from the Member with respect to the subject matter of the
`record.
`A record in this system of records may be disclosed, as a routine use, to a contractor of the
`Agency having need for the information in order to perform a contract. Recipients of
`information shall be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552a(m).
`A record related to an International Application filed under the Patent Cooperation Treaty in
`this system of records may be disclosed, as a routine use, to the International Bureau of the
`World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disclosed, as a routine use, to another federal
`agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to
`the Atomic Energy Act (42 U.S.C. 218(c)).
`A record from this system of records may be disclosed, as a routine use, to the Administrator,
`General Services, or his/her designee, during an inspection of records conducted by GSA as
`part of that agency's responsibility to recommend improvements in records management
`practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall
`be made